Previous 10 | Next 10 |
Sesen Bio (SESN) is gearing up for a major event in the coming weeks. That's because it will host a conference call to both release earnings and give an update on one of its late-stage studies using Vicinium to treat patients with bladder cancer. This will take place on May 13, 2019, at 8:...
NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Sesen Bio, Inc. (NASDAQ: SESN) , a late-stage clinical company, focused on design...
Gainers: Roan Resources (NYSE: ROAN ) +41% . Alterity Therapeutics (NASDAQ: ATHE ) +32% . Changyou.com (NASDAQ: CYOU ) +22% . Sohu.com (NASDAQ: SOHU ) +19% . Enlivex Therapeutics (NASDAQ: ENLV ) +19% . Gardner Denver Holdings (NYSE: GDI ) +16% . Provention Bio (NASDAQ: PRVB ) ...
Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 13, 2019 at 8:00 a.m. EDT to review operating res...
Gainers: Regional Health Properties (NYSEMKT: RHE ) +183% . Moleculin Biotech (NASDAQ: MBRX ) +51% . The KeyW Holding (NASDAQ: KEYW ) +43% . Key Energy Services (NYSE: KEG ) +32% . Iconix Brand Group (NASDAQ: ICON ) +25% . Lantronix (NASDAQ: LTRX ) +15% . Denbury Resources (NYS...
April 17, 2019 Palm Beach, FL – April 17, 2019 – The American Association for Cancer Research (AARC) recently released an article that interviewed Nobel Laureate, Fellow of the AACR Academy, and immunotherapy pioneer James P. Allison, PhD and AACR President-elec...
Micro cap Sesen Bio ( SESN +23.9% ) is up more than a 7x surge in volume. No particular news accounts for the action but a key catalyst should happen later this quarter. More news on: Sesen Bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
CORAL GABLES, FL / ACCESSWIRE / March 28, 2019 / The healthcare stock market has been a hotbed of excitement in the first few months of 2019 as companies in the industry have focused their efforts on developing innovative technologies and treatments for consumers. The fact of the matter is...
POINT ROBERTS, Wash. and DELTA, British Columbia, March 27, 2019 (GLOBE NEWSWIRE) -- Investorideas.com , a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market ...
On March 4, Sesen Bio's ( SESN ) President and CEO Dr. Thomas Cannell held a conference call, primarily to update the status and progress of Vicinium. A Brief Background Vicinium is being developed for non-muscle invasive bladder cancer (NMIBC), a very common cancer for which no new trea...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...